Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 6.39 USD 6.15%
Market Cap: 943m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Adaptive Biotechnologies Corp
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptive Biotechnologies Corp
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Depreciation & Amortization
-$11.5m
CAGR 3-Years
-89%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Depreciation & Amortization
-$1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Depreciation & Amortization
-$72.7m
CAGR 3-Years
-6%
CAGR 5-Years
-8%
CAGR 10-Years
-10%
Agilent Technologies Inc
NYSE:A
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Depreciation & Amortization
-$1.1B
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
942.9m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.94 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's Depreciation & Amortization?
Depreciation & Amortization
-11.5m USD

Based on the financial report for Sep 30, 2024, Adaptive Biotechnologies Corp's Depreciation & Amortization amounts to -11.5m USD.

What is Adaptive Biotechnologies Corp's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-47%

Over the last year, the Depreciation & Amortization growth was 23%. The average annual Depreciation & Amortization growth rates for Adaptive Biotechnologies Corp have been -89% over the past three years , -47% over the past five years .

Back to Top